• Je něco špatně v tomto záznamu ?

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

AM. Kamat, AB. Apolo, M. Babjuk, TJ. Bivalacqua, PC. Black, R. Buckley, MT. Campbell, E. Compérat, JA. Efstathiou, P. Grivas, S. Gupta, NJ. Kurtz, D. Lamm, SP. Lerner, R. Li, DJ. McConkey, J. Palou Redorta, T. Powles, SP. Psutka, N. Shore, GD....

. 2023 ; 41 (35) : 5437-5447. [pub] 20231004

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000271

PURPOSE: There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel. METHODS: Through open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually). RESULTS: The consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text. CONCLUSION: These recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.

BCG Oncology Phoenix AZ

Carolina Urologic Research Center Myrtle Beach SC

Center for Cancer Research National Cancer Institute NIH Bethesda MD

Clinical Research Division Fred Hutchinson Cancer Center Seattle WA

Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston TX

Department of Genitourinary Oncology H Lee Moffitt Cancer Center Tampa FL

Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH

Department of Medicine Division of Oncology University of Washington

Department of Pathology Medical University of Vienna Vienna Austria

Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston MA

Department of Urologic Sciences University of British Columbia Vancouver British Columbia Canada

Department of Urology Fundació Puigvert Universitat Autònoma de Barcelona Barcelona Spain

Department of Urology North York General Hospital Toronto Ontario Canada

Department of Urology Rush University Medical Center Chicago IL

Department of Urology Teaching Hospital Motol 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology The University of Texas MD Anderson Cancer Center Houston TX

Department of Urology University of Washington Fred Hutchinson Cancer Center Seattle WA

Division of Urology Department of Surgery University of Pennsylvania Philadelphia PA

EAU NMIBC Guidelines Panel Arnhem the Netherlands

Icahn School of Medicine at Mount Sinai Tisch Cancer Institute New York NY

Johns Hopkins Greenberg Bladder Cancer Institute Johns Hopkins University Baltimore MD

Patient Advocate Bladder Cancer Advocacy Network Bethesda MD

Queen Mary University of London London United Kingdom

Radboud University Medical Center Nijmegen the Netherlands

Scott Department of Urology Dan L Duncan Cancer Center Baylor College of Medicine Houston TX

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000271
003      
CZ-PrNML
005      
20240213093036.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.23.00307 $2 doi
035    __
$a (PubMed)37793077
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kamat, Ashish M $u Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX $1 https://orcid.org/0000000335469928
245    10
$a Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group / $c AM. Kamat, AB. Apolo, M. Babjuk, TJ. Bivalacqua, PC. Black, R. Buckley, MT. Campbell, E. Compérat, JA. Efstathiou, P. Grivas, S. Gupta, NJ. Kurtz, D. Lamm, SP. Lerner, R. Li, DJ. McConkey, J. Palou Redorta, T. Powles, SP. Psutka, N. Shore, GD. Steinberg, R. Sylvester, JA. Witjes, MD. Galsky
520    9_
$a PURPOSE: There is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel. METHODS: Through open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually). RESULTS: The consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text. CONCLUSION: These recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.
650    _2
$a lidé $7 D006801
650    _2
$a klinické zkoušky jako téma $7 D002986
650    12
$a nádory močového měchýře $x patologie $7 D001749
650    _2
$a adjuvancia imunologická $x terapeutické užití $7 D000276
650    12
$a karcinom z přechodných buněk $7 D002295
650    _2
$a imunoterapie $7 D007167
655    _2
$a časopisecké články $7 D016428
700    1_
$a Apolo, Andrea B $u Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD $1 https://orcid.org/0000000194091836
700    1_
$a Babjuk, Marek $u Department of Urology, Teaching Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000231157428
700    1_
$a Bivalacqua, Trinity J $u Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Black, Peter C $u Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia, PA $1 https://orcid.org/0000000229197068
700    1_
$a Buckley, Roger $u Department of Urology, North York General Hospital, Toronto, Ontario, Canada
700    1_
$a Campbell, Matthew T $u Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX $1 https://orcid.org/0000000319154491
700    1_
$a Compérat, Eva $u Department of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Efstathiou, Jason A $u Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA $1 https://orcid.org/0000000309960350
700    1_
$a Grivas, Petros $u Department of Medicine, Division of Oncology, University of Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA $1 https://orcid.org/0000000339653394
700    1_
$a Gupta, Shilpa $u Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH $1 https://orcid.org/000000028775503X
700    1_
$a Kurtz, Neil J $u Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
700    1_
$a Lamm, Donald $u Patient Advocate, Bladder Cancer Advocacy Network (BCAN), Bethesda, MD
700    1_
$a Lerner, Seth P $u BCG Oncology, Phoenix, AZ $1 https://orcid.org/0000000263792581
700    1_
$a Li, Roger $u Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX $1 https://orcid.org/0000000312747200
700    1_
$a McConkey, David J $u Department of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL
700    1_
$a Palou Redorta, Joan $u Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD
700    1_
$a Powles, Thomas $u Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000177604724
700    1_
$a Psutka, Sarah P $u Queen Mary University of London, London, United Kingdom $1 https://orcid.org/0000000242077490
700    1_
$a Shore, Neal $u Department of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA $1 https://orcid.org/0000000157670548
700    1_
$a Steinberg, Gary D $u Carolina Urologic Research Center, Myrtle Beach, SC
700    1_
$a Sylvester, Richard $u Department of Urology, Rush University Medical Center, Chicago, IL $1 https://orcid.org/000000030529862X
700    1_
$a Witjes, J Alfred $u EAU NMIBC Guidelines Panel, Arnhem, the Netherlands
700    1_
$a Galsky, Matthew D $u Radboud University Medical Center, Nijmegen, the Netherlands $1 https://orcid.org/0000000176559378
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 41, č. 35 (2023), s. 5437-5447
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37793077 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093033 $b ABA008
999    __
$a ok $b bmc $g 2049123 $s 1209965
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 35 $d 5437-5447 $e 20231004 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace